Seres Therapeutics names Richard Kender as interim CEO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St rebounds with broad gains as oil slides sharply
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates
March 2, 2026 4:05 PM ESTAccomplished pharmaceutical executive brings extensive business development, licensing and finance experience
Seres is implementing a focused corporate strategy to advance live biotherapeutic programs in inflammatory and immune diseases and support the readout of investigator-sponsored SER-155 study in immune checkpointrelated enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, expected in Q2 2026
SER-155 is Phase 2 ready for patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematologic malignancies (cancers of the blood, bone marrow, and lymph nodes); efforts to secure funding for... More
